Search
for
Sort by
Research 31–60 of 108
- Dasatinib-Induced Leukotrichia in a Patient With Chronic Myelogenous Leukemia
- The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Smoker’s Mustache Revisited: Upper Lip Hair Yellow Discoloration Associated With Tobacco
- A Comprehensive Review on Current and Future Trends of Nanoemulsions in Modern Cosmetics and Pharmaceuticals
- Cutaneous Side Effects of Chemotherapy and Radiotherapy
- Cutaneous drug reactions
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Comparative study of the chemical profile, cytotoxic activity, and molecular docking of Serenoa repens extract and a pharmaceutical product
- Sorafenib-induced Facial Acneiform Eruption
- Hair Changes due to Drugs
- Poster Abstracts
- Index
- Tyrosine Kinase Inhibitors against Cancer: Their Safety in 216 Moroccan Patients
- Anticancer effects of metformin on neuroendocrine tumor cells in vitro
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Chemotherapy-induced alopecia
- Challenges in the Physical Characterization of Lipid Nanoparticles
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- RASopathic Skin Eruptions during Vemurafenib Therapy
- Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work
- Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
- Alleviation of Multidrug Resistance by Flavonoid and Non-Flavonoid Compounds in Breast, Lung, Colorectal and Prostate Cancer
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
- Assessing the cost-effectiveness of DNA origami nanostructures for targeted delivery of anti-cancer drugs to tumours